Doctors

He is currently the Director of the Radiation Therapy Department at Peking University First Hospital, the Director of the Radiation Oncology Department at Peking University, and the Deputy Director of the Peking University Proximity Treatment Center. Committed to tumor radiotherapy, comprehensive diagnosis and treatment, scientific research, and teaching for nearly 40 years, with rich clinical experience and profound theoretical knowledge, I have conducted in-depth research on photon and proton heavy ion therapy for urological tumors, chest tumors, and pediatric tumors. Six research results have been cited by the world's most authoritative NCCN guidelines, ESTRO guidelines, EAU guidelines, and ARS guidelines. As the first author or corresponding author, I have published over 120 journal papers, including over 60 SCI papers. I have been approved for 5 National Natural Science Foundation projects, 1 Key Project of the State Council Counselor's Office, 1 Special Project of the National Key R&D Plan of the Ministry of Science and Technology, and dozens of provincial and ministerial level projects. Participated in the development of the Resident Physician Training Textbook "Tumor Radiotherapy" by the National Health and Family Planning Commission multiple times. The postgraduate textbook "Tumor Radiotherapy" for the 13th Five Year Plan of the National Health and Family Planning Commission was also developed. Received the 5th "People's Famous Doctor · Outstanding Achievements" Award.

Academic and resume positions

Awarded the 5th "People's Famous Doctor · Outstanding Achievements" Award by People's Daily;

Chairman of the Asian Radiotherapy Alliance (FARO);

Standing Committee Member and Prostate Member of the Radiation Tumor Treatment Credit Committee of the Chinese Medical Association; Leader of the Cancer Group;

Chairman of the Asian Radiotherapy Alliance (FARO);

Japanese Society of Radiology and Oncology (JASTRO) specially hired overseas senior experts;

Chairman of the Radiation Oncology Professional Committee of the Chinese Research Hospital Association;

Administrative Director of the Radiotherapy Department of Peking University First Hospital;

Director of the Department of Radiation Oncology, Department of Medicine, Shangjing University;

Deputy Director of Peking University Proximity Therapy Center;

Vice President of the China Japan Medical Science and Technology Exchange Association;

Vice Chairman and Secretary General of the Proton Heavy Ion Radiotherapy Special Committee of the China Association for the Promotion of Human Health Technology;

Leader of the Proton Heavy Ion Expert Advisory Committee of the Beijing Medical Association;

Vice Chairman of the Neurology Committee of the China Anti Cancer Association;

Member of the Cancer Radiotherapy Expert Committee of the Chinese Society of Clinical Oncology (CSCO);

Vice Chairman of the Radiation Oncology Professional Committee of Beijing Medical Association;

Member of the Cancer Branch of the Beijing Medical Association;

Vice Chairman of the Radiation Oncology Professional Committee of the Beijing Anti Cancer Association;

Executive Committee Member of the 5th Radiation Oncology Branch of the Chinese Medical Association;

Chairman of the Radiation Oncology Professional Committee of the Sino Japanese Medical Science and Technology Exchange Association;

Consultant of the Radiation Oncology Branch of the Chinese Medical Association;

Member of the peer review expert group of the National Natural Science Foundation of China;

Leader of the Esophageal Cancer Professional Group of the 5th Chinese Society of Radiology and Oncology;

Executive Director of the Radiation Therapy Specialist (Technician) Branch of the Beijing Medical Association;

Joint research between Peking University First Hospital and Japan National Cancer Research Center;

Editorial board member of the Chinese Journal of Radiation Oncology;

Editorial board member of the Chinese Journal of Radiology and Protection;

Appointed reviewer of Chinese Cancer Clinical Doshi;

Editorial board member of the Journal of Neuropharmacology;

Editorial board member of the Chinese Journal of Neurology.

Technology and Clinical Innovation

Proton heavy ion therapy: a pioneer and leader in advanced radiotherapy technology

As early as the early 1990s, I participated in research related to proton heavy ions during my study abroad in Japan, and actively promoted the deep integration of proton therapy with industry, academia, and research after returning home. At present, he has served as the vice chairman and secretary-general of the Proton and Heavy Ion Radiotherapy Special Committee of the Chinese Association for the Promotion of Human Health Science and Technology, the leader of the Proton and Heavy Ion Radiotherapy Expert Advisory Committee of the Beijing Medical Association, and has been invited by many institutions or hospitals, such as the Institute of Modern Physics of the Chinese Academy of Sciences, to serve as a guest researcher or general consultant and other positions in the tripartite cooperation between Hebei Yizhou Cancer Hospital, Peking University First Hospital and the Beaumont Proton Therapy Center of the United States, Conduct weekly joint rounds, review and optimize the treatment plans and target areas of all proton therapy patients at Yizhou Hospital, ensuring that all patients can receive internationally advanced diagnostic and treatment services. At the same time, clinical and scientific research are driven by two wheels, and the three parties jointly carry out high-level joint research to jointly cultivate graduate students in the field of proton radiation physics, Currently, there is a 'Redefine the Role oiProton Beam Therapy for the Local-Advanced Non Small Cell Lung Cancer Assisting the Reduction of ActHematological Toxicity' investing the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic BodRadiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: Comparison Between Photon and Proton Beam Therapy ' Multiple research results have been published internationally.

Prostate cancer: Establishing international advanced diagnostic and treatment standards, rewriting international authoritative guidelines for prostate cancer three times

Drawing on the delineation and quality control standards of prostate cancer radiotherapy target areas from 8 renowned European and American hospitals in the field of prostate cancer radiotherapy, combined with the characteristics of prostate adenoma incidence in China, drawing on strengths and weaknesses, and carefully summarizing, establish the prostate cancer radiotherapy standards of Peking University First Hospital. Under the same therapeutic effect, the rectal protection effect is better, and the incidence of side effects is better than that of foreign countries. In 2022, the research results on the selection of radiation dose after radical prostatectomy were adopted by the prostate cancer diagnosis and treatment guidelines jointly developed by six societies including the European Society of Urology (EAU). This is the third revision of the international prostate cancer radiation treatment standards after two studies changed the 2018 ESTRO prostate cancer radiation treatment guidelines.

Bladder cancer: establish a characteristic bladder preservation mode - higher local control rate and less side effects

Establishing a characteristic bladder preservation treatment model that can not only provide high-dose radiation to the local tumor area, but also protect the normal bladder wall from only receiving low-dose prophylactic radiation. Research results show that the local control rate of the tumor can reach 95%, and the side effects are smaller, which is significantly better than foreign standard treatment plans. In 2022, a study that confirmed that postoperative adjuvant radiotherapy can reduce local recurrence of renal and ureteral cancer patients and described the map of local recurrence locations in detail was cited by NCCN bladder cancer guidelines. Kidney cancer: Exploring a new mode of combining stereotactic radioablation therapy with targeted and immunotherapy to break through treatment bottlenecks. Taking the lead in China, we are conducting research on the combination of stereotactic radioablation therapy with targeted and immunotherapy for kidney cancer. While supplementing systemic therapy, we aim to enhance the local control rate of kidney cancer lesions, which is expected to break through the current treatment bottleneck and bring new hope to patients with recurrent/metastatic kidney cancer!

Esophageal cancer: Two studies cited by the International Esophageal Cancer Guidelines

The original research findings on "Subclinical Target Mapping for Esophageal Cancer Radiotherapy" were adopted by the 2013 NCCN Esophageal Cancer Treatment Guidelines and continue to be used today. Later, they were cited in textbooks from various countries, benefiting esophageal cancer patients worldwide. Another comparative study on esophageal cancer surgery and chemotherapy was cited five times by the American Radium Society (ARS guidelines) in 2021, providing guidance for the initial treatment selection of resectable esophageal cancer in the real world.